RxDoctor Payments Data

Matthew Whitbeck, MD

Cardiovascular Disease · Coon Rapids, MNNPI 1932316924

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (52.1%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Abbott at 30.3% of the total. 2025 is the largest year on record at $41,681, 4.2 times the $10,040 reported in 2019. Among cardiovascular disease clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$162,520in general payments, 2019–2025

Across 242 payments — averaging $671.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$49K
  • Boston Scientific$41K
  • Cardiovascular Systems Inc.$24K
  • Shockwave Medical, Inc$20K
  • Abiomed$19K
  • Teleflex LLC$4K
  • plus $6K from 15 others
$600,247in research payments, 2019–2025

Across 99 payments — averaging $6063.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$573K
  • Cathworks, Inc.$23K
  • Philips North America LLC$4K

What the payments were for

  • Consulting fees$84,66052%
  • Speaking & faculty fees$65,08540%
  • Travel & lodging$5,4223%
  • Food & beverage$7,3535%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$162,520 in reported general payments places this provider in the 95th percentile of 451 cardiovascular disease providers in Minnesota.

See all cardiovascular disease providers in Minnesota

Medicare billing

Part B allowed, 2024
$89,102
Medicare patients
366
Services billed
922

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban46$53,703
XareltoRivaroxaban31$30,210
BrilintaTicagrelor13$16,620
Metoprolol Succinate133$2,172
Rosuvastatin Calcium115$2,032
ClopidogrelClopidogrel Bisulfate132$1,901
Prasugrel Hcl23$1,484
Losartan Potassium74$1,088
Atorvastatin Calcium80$1,032
Ezetimibe40$819
Lisinopril58$678
Carvedilol55$548
Hydralazine Hcl16$496
Metoprolol Tartrate79$431
Amlodipine Besylate46$385

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Coon Rapids

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →